Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Catherine Scott"'
Autor:
Jie Wang-Jairaj, Catherine Scott-Wilson, Mark T. Dransfield, David B Rubin, Dawn Midwinter, John R. Cockcroft, Courtney Crim, Surya P. Bhatt
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Surya P Bhatt,1 Mark T Dransfield,1 John R Cockcroft,2 Jie Wang-Jairaj,3 Dawn A Midwinter,3 David B Rubin,4 Catherine A Scott-Wilson,4 Courtney Crim4 1Division of Pulmonary, Allergy and Critical Care Medicine and UAB Lung Health Center, University of
Autor:
Catherine Scott-Wilson, Henry Covelli, Courtney Crim, Isabelle Schenkenberger, Amanda Emmett, Bonavuth Pek
Publikováno v:
International Journal of Chronic Obstructive Pulmonary Disease
Henry Covelli,1 Bonavuth Pek,2 Isabelle Schenkenberger,3 Catherine Scott-Wilson,4 Amanda Emmett,5 Courtney Crim4 1Kootenai Health, Coeur d’Alene, ID, USA; 2Clinique de Pneumologie et de Sommeil de Lanaudière, Quebec, Canada; 3Klinische Forschung,
Publikováno v:
Respiratory medicine. 123
Background The contribution of fluticasone furoate (FF) on lung function in the FF/vilanterol (VI) 100/25 μg combination has been demonstrated numerically, but not statistically. Methods This multicentre, randomised, double-blind, controlled trial (
Autor:
Leonardo M. Fabbri, Courtney Crim, Gregory Feldman, Joseph Boscia, Peter M.A. Calverley, Fernando J. Martinez, Catherine Scott-Wilson, Sally Kilbride
Publikováno v:
Respiratory Medicine. 107(4):550-559
SummaryBackgroundOnce-daily combination treatment is an attractive maintenance therapy for COPD. However, the dose of inhaled corticosteroid to use in a once-daily combination is unknown. We compared two strengths of fluticasone furoate (FF) plus vil
Autor:
William R. Lumry, Courtney Crim, Michael M. Conway, Nancy Herje, Catherine Scott, David S. Pearlman, Wei W. Wu, Craig LaForce
Publikováno v:
Annals of Allergy, Asthma & Immunology. 96:51-59
Inhaled corticosteroids (ICSs) delivered by metered-dose inhalers that contain chlorofluorocarbon propellants are being discontinued because of the harmful effects of chlorofluorocarbon on the ozone layer. Therefore, some metered-dose inhaler product
Autor:
Catherine Scott, Paul Chervinsky, Courtney Crim, Steven F. Weinstein, Nancy Herje, Wei Wu, Michael Noonan, Jacob L. Pinnas
Publikováno v:
Journal of Asthma. 42:865-871
In this randomized, double-blind, placebo-controlled trial, 397 patients with moderate to severe asthma, previously treated with bronchodilators alone, received fluticasone propionate 88, 220, or 440 microg twice daily, or placebo via metered dose in
Autor:
Steven F. Weinstein, Leslie Baitinger, Catherine Scott, David B. Peden, David S. Pearlman, Paul Dorinsky, Karen W. House, Martha V. White, Shu Yen Ho, John J. Condemi
Publikováno v:
Journal of Asthma. 41:797-806
The objective of this study was to compare the efficacy and safety of fluticasone propionate (FP) (44 microg)/salmeterol (21 microg) delivered as two inhalations twice daily via a single hydrofluoroalkane (HFA 134a) metered dose inhaler (MDI) (FSC) w
Autor:
Edward Kerwin, Catherine Scott-Wilson, Neil Barnes, Lisa Sanford, Courtney Crim, Stephen I. Rennard, Alvar Agusti
Publikováno v:
Respiratory medicine. 107(4)
SummaryBackgroundFluticasone furoate (FF)/vilanterol (VI) is a novel once-daily inhaled corticosteroid/long-acting β2-agonist combination therapy for COPD. We aimed to assess the efficacy and safety of two strengths of FF/VI (100/25 μg; 50/25 μg)
Autor:
Hector Ortega, Shu-Yen Ho, Leslie Andersen, Heather M. Edin, Catherine Scott-Wilson, Lynne Schoaf
Publikováno v:
Annals of allergy, asthmaimmunology : official publication of the American College of Allergy, Asthma,Immunology. 102(4)
Background Current asthma guidelines emphasize domains of impairment and risk for assessing severity and control, noting the need to consider separately the effects of asthma on asthma quality of life and functional capacity. Proper treatment to cont
Autor:
Robert L. Cowie, Paul K. Keith, Paul Dorinsky, Catherine Scott-Wilson, Karen W. House, Louis-Philippe Boulet
Publikováno v:
Clinical therapeutics. 29(7)
Many patients with asthma require an inhaled long-acting beta(2)-agonist (LABA) in addition to an inhaled corticosteroid to adequately control their disease.The purpose of this study was to assess the long-term tolerability of a salmeterol xinafoate/